TY - JOUR T1 - In search of “hepatic factor:” Lack of evidence for ALK1 ligands BMP9 and BMP10 JF - medRxiv DO - 10.1101/2020.07.09.20148320 SP - 2020.07.09.20148320 AU - Teresa L. Capasso AU - Sara M. Trucco AU - Morgan Hindes AU - Tristin Schwartze AU - Jamie L. Bloch AU - Jacqueline Kreutzer AU - Stephen C. Cook AU - Cynthia S. Hinck AU - Davide Treggiari AU - Brian Feingold AU - Andrew P. Hinck AU - Beth L. Roman Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/11/2020.07.09.20148320.abstract N2 - In children with single ventricle physiology, the Glenn procedure is performed to redirect venous return from the superior vena cava directly to the pulmonary arteries and route venous return from the inferior vena cava exclusively to the systemic circulation. Although this surgery successfully palliates the hemodynamic stress experienced by the single ventricle, patients frequently develop pulmonary arteriovenous malformations (PAVMs). Interestingly, PAVMs may regress upon rerouting of hepatic venous effluent to the pulmonary vasculature, suggesting the presence of a circulating “hepatic factor” that is required to prevent PAVMs. Here, we test the hypothesis that hepatic factor is bone morphogenetic protein 9 (BMP9) and/or BMP10. These circulating ligands are produced by the liver and activate endothelial endoglin (ENG)/ALK1 signaling, and mutations in ENG and ALK1 cause hereditary hemorrhagic telangiectasia, a genetic disease associated with AVM development. However, we found no within-subject variation in BMP9, BMP10, or BMP9/10 plasma concentrations when sampled from five cardiovascular sites, failing to support the idea that the Glenn would limit access of these ligands to the lung vasculature. Unexpectedly, however, we found a significant decrease in all three ligand concentrations in Glenn cases versus controls. Our findings suggest that BMP9/BMP10/ENG/ALK1 signaling may be decreased in the Glenn vasculature but fail to implicate these ligands as hepatic factor.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUniversity of Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Vitalant Innovator Award, NIH R01HL133009, NIH R01HL136566, DOD WX18WH-17-1-0429.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approve by University of Pittsburgh IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are archived on secure servers maintained by the University of Pittsburgh Department of Human Genetics ER -